Allon Therapeutics completes patient dosing in phase 1b trial of AL-208 in neurodegenerative disease

By Lisa Kerner

Erie, Pa., May 30 - Allon Therapeutics Inc. said it has completed dosing 8 healthy and 13 diabetic patients in its a phase 1b human clinical trial evaluating the safety, tolerability and pharmacokinetics of AL-208 as a treatment for neurodegenerative indications where multiple doses are required.

The company expects to release results from the double-blind, placebo-controlled study before the end of the third quarter, according to a news release.

A phase 2 trial is slated to begin within a month evaluating AL-208 as a treatment for the mild cognitive impairment following coronary artery bypass graft surgery.

AL-108 is also being studied as a treatment for Alzheimer's disease.

Allon a development-stage biotechnology company based in Vancouver, B.C.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.